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Abstract: Cellular FLICE (FADD-like IL-1beta-converting enzyme)-inhibitory protein  
(c-FLIP) is a major resistance factor and critical anti-apoptotic regulator that inhibits tumor 
necrosis factor-alpha (TNF-alpha), Fas-L, and TNF-related apoptosis-inducing ligand 
(TRAIL)-induced apoptosis as well as chemotherapy-triggered apoptosis in malignant cells. 
c-FLIP is expressed as long (c-FLIPL), short (c-FLIPS), and c-FLIPR splice variants in human 
cells. c-FLIP binds to FADD and/or caspase-8 or -10 in a ligand-dependent and-independent 
fashion, which in turn prevents death-inducing signaling complex (DISC) formation and 
subsequent activation of the caspase cascade. Moreover, c-FLIPL and c-FLIPS are known 
to have multifunctional roles in various signaling pathways, as well as activating and/or 
upregulating several cytoprotective signaling molecules. Upregulation of c-FLIP has been 
found in various tumor types, and its downregulation has been shown to restore apoptosis 
triggered by cytokines and various chemotherapeutic agents. Hence, c-FLIP is an important 
target for cancer therapy. For example, small interfering RNAs (siRNAs) that specifically 
knockdown the expression of c-FLIPL in diverse human cancer cell lines augmented 
TRAIL-induced DISC recruitment and increased the efficacy of chemotherapeutic agents, 
thereby enhancing effector caspase stimulation and apoptosis. Moreover, small molecules 
causing degradation of c-FLIP as well as decreasing mRNA and protein levels of c-FLIPL 
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and c-FLIPS splice variants have been found, and efforts are underway to develop other  
c-FLIP-targeted cancer therapies. This review focuses on (1) the functional role of c-FLIP 
splice variants in preventing apoptosis and inducing cytokine and drug resistance; (2) the 
molecular mechanisms that regulate c-FLIP expression; and (3) strategies to inhibit c-FLIP 
expression and function. 
Keywords: c-FLIP; apoptosis; death receptors; cancer; chemotherapy 
 
1. Introduction 
Cytotoxic anticancer agents continue to serve as the mainstay modality of systemic therapy in 
treating human malignancies that have disseminated from the primary tumor site and cannot be 
managed solely by surgical removal or radiation. The major limitation of cancer chemotherapy has 
proven to be drug resistance, whether acquired by the malignancy after transient disease remission 
(e.g., after breast cancer chemotherapy), or intrinsic to the malignancy (e.g., colon cancer, pancreatic 
cancer, glioblastoma, and prostate cancer are typically refractory to cancer chemotherapy). Several 
mechanisms have been found to cause chemotherapeutic resistance in cancer cells in vitro [1-4], but 
whether these mechanisms are also operative in the same manner in vivo requires further study. 
Understanding the mechanisms of resistance to chemotherapeutic agents will assist in the design of 
more effective strategies to overcome resistance in cancer cells. 
Defects in apoptotic signaling and redundant survival mechanisms in malignant cells contribute to 
drug resistance in various cancer types [5,6]. Therefore, strategies to lower the threshold for triggering 
apoptosis in various cancers may lead to new and more effective therapeutic regimens. Acutely 
induced chemosensitization occurs when a pro-apoptotic signaling program induced in neoplastic cells 
by a chemotherapy drug includes disabling of a cytoprotective anti-apoptotic response. This is illustrated by 
our discovery that acute exposure of human leukemia cells to Taxol induced a pro-apoptotic program that 
entails coordinate caspase activation and downregulation of the anti-apoptotic protein cellular  
FLICE-like inhibitory protein (c-FLIP), a catalytically inactive caspase-8/-10 homologue [7]. c-FLIP 
variants are involved in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and 
chemotherapeutic drug resistance in a wide range of human malignancies [7-13]. The fact that Taxol has 
the added benefit of disabling a specific cytoprotective signal in neoplastic cells in conjunction with 
inducing apoptosis signaling is consistent with its often superior efficacy compared with other apoptosis-
inducing chemotherapy drugs in managing diverse neoplastic diseases. Furthermore, a combination of 
Taxol/c-FLIP targeted therapy may improve the therapeutic response to Taxol by enhancing 
downregulation of c-FLIP variants in concert with drug-induced apoptosis signaling [7]. 
We have reported that upregulation of the pro-apoptotic TRAIL receptor DR5 may actually occur 
during the development of chemotherapy-induced drug resistance phenotype in cancer cells [14]. 
Moreover, upregulation of the pro-apoptotic signaling proteins or suppression of specific anti-survival 
signaling pathways by agents directed to increase pro-apoptotic proteins may acutely induce 
chemosensitization of resistant cancer cells. For instance, we previously demonstrated TRAIL 
treatment selectively triggered apoptosis in P-glycoprotein (P-gp ABCB1)-overexpressing multidrug 
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resistant (MDR) cells [14-16]. Moreover, hypersensitivity to TRAIL was either due to (1) increased 
TRAIL binding to the TRAIL receptor DR5 in these cells compared to their drug sensitive 
counterparts [15]; or (2) up-regulation of DR5 and concomitant degradation of P-gp [14], the release of 
cytochrome c from mitochondria, activation of caspases-9 and -3 [14], as well as down-regulation of 
c-FLIP and the DNA-dependent protein kinase catalytic subunit (DNA-PKcs) by activation of 
caspase-3 [17]. These data also provided important determinants of TRAIL-induced sensitization of 
MDR cells to MDR-related agents [14,17]. Therefore, these results hold significant clinical 
implications for the use of TRAIL or TRAIL and chemotherapeutic drugs for treating cancers with the 
MDR phenotype. TRAIL holds enormous promise as a cancer therapeutic due to its highly selective 
apoptosis-inducing action on neoplastic versus normal cells [18,19]. Moreover, a recently published 
Phase I clinical trial revealed that recombinant TRAIL administration is safe and well tolerated, and 
that dose escalation achieved peak TRAIL serum concentrations equivalent to those associated with 
preclinical antitumor efficacy [20] However, to exploit the opportunity to successfully treat cancers 
with TRAIL, the problems of TRAIL resistance in a variety of tumor cells must first be overcome [21-23]. 
It is now recognized that the mechanism of action of chemotherapy drugs often involves the 
induction of cancer cell apoptosis, and that apoptosis resistance is a major contributing factor in 
chemotherapeutic drug resistance. Therefore, restoring apoptosis signaling in cancer cells with targeted 
therapeutics has enormous potential to improve the outcome of cancer chemotherapy by reversing a 
major mechanism of drug resistance. As we previously reported [24], c-FLIP is a critical target for 
therapeutic intervention aimed at inhibiting its transcription and posttranscription. In this review, we 
assess the outlook for improving the outcome of cancer therapy by targeting c-FLIP and exploring the 
possibility of increasing its degradation and/or decreasing its expression in order to provide a 
potentially safe approach to treat cancer. Novel modalities of cancer therapy that improve the efficacy 
of TRAIL as well as chemotherapeutic drugs and lessen the toxicity of these agents by targeting 
specific c-FLIP isoforms is discussed. 
2. Apoptosis Signaling Pathways 
Apoptosis is a mechanism of programmed cell death involving signal transduction pathways that 
induce cells to self-destruct in response to organismal cues, e.g., digit formation in vertebrate limbs 
during embryonic development, environmental hazards (e.g., radiation-induced DNA damage), or 
anticancer therapeutics (e.g., chemotherapeutic agents and cytokines). Two well-studied pathways are 
involved in apoptosis: the
 
mitochondrion-initiated pathway (Figure 1) and the cell surface death
 
receptors pathway (Figure 1) [25-27]. In the mitochondrial pathway, cytochrome
 
c, certain caspases, 
apoptosis-inducing factor, Smac/DIABLO,
 
and
 
other apoptosis-inducing factors are released from the 
mitochondrial intramembrane
 
space to the cytosol [28]. Once released, cytochrome c and dATP
 
bind to 
apoptotic proteinase-activating factor-1 (Apaf-1), and
 
this complex along with adenine nucleotides 
promote procaspase-9
 
autoactivation [29], which in turn activates caspases-2, -3,
 
-6, -7, -8, and -10. 
Apoptosis triggered by various stimuli requires direct activation of Bax and BAK at the mitochondria 
by a member of the Bcl-2 homology domain-3 (BH3)-only family of proteins including Bid, Bim, or 
PUMA [30]. The various anti- and pro-apoptotic members of the Bcl-2 family form a network of 
interactions that ultimately regulate the permeabilization of the mitochondrial outer membrane and 
Cancers 2011, 3              
 
1642 
release of apoptogenic factors such as cytochrome c to the cytoplasm [31]. Apoptosis initiated by the 
endoplasmic reticulum (ER) stress signaling pathway is also mainly dependent on the
 
release of 
cytochrome c from the mitochondrial intermembrane
 
space into the cytosol [32]. This release is 
associated with the opening
 
of the permeability transition pore (PTP) and a collapse in
 
the 
mitochondrial transmembrane potential ( m) due to the intake of Ca
2+
 following its release into the 
cytosol
 
from the ER. Recent work has
 
demonstrated that certain members of the Bcl-2 family are 
present
 
on the ER where they appear to have a comprehensive
 
function in the maintenance of ER 
homeostasis, participation in ER stress signal transduction pathways, and apoptosis [32]. 
In the death receptor-mediated apoptosis pathway (e.g., Fas/Fas ligand interaction or TRAIL/DR5 
interaction and cell death), the initiator caspases-8 and -10 activate the downstream caspases including 
caspase-3 [18,19,24]. Active caspases-8 and -10 are known to cleave a pro-apoptotic Bcl-2 family 
member, Bid, and the truncated Bid induces mitochondrial cytochrome c release [26-29], thereby 
linking the two pathways. After activation, both caspases-8 and -9 activate caspase-3, which in turn 
cleaves other caspases and many cellular proteins including fodrin, various kinases, poly(ADP-ribose) 
polymerase, gelsolin, and DNA fragmentation factor-45 (DFF45) [26,33-37]. A third pathway has also 
been identified [38]. In this pathway, as Slee et al. [38] showed, BID is cleaved in response to several 
death-inducing stimuli (staurosporine, UV radiation, cycloheximide, etoposide) and that BID cleavage 
was blocked by Bcl-2, suggesting that degradation of BID occurred distal to cytochrome c release. 
Moreover, addition of cytochrome c to Jurkat post-nuclear extracts triggered cleavage of BID at Asp-
59 which was catalysed by caspase-3 rather than caspase-8. These results provide evidence that 
caspase-3 mediated cleavage of BID represents a feedback loop for the amplification of mitochondrial 
cytochrome c release during cytotoxic drug and UV radiation-induced apoptosis [38]. 
Figure 1. Schematic overview of the multifunctional roles of c-FLIP in the TRAIL-
triggered apoptosis pathway as well as activating various anti-apoptotic and cell survival 
signaling pathways.  
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3. Cellular FLICE-Like Inhibitory Protein (c-FLIP) 
3.1. Structure of c-FLIP 
Originally, viral FLICE-inhibitory proteins (v-FLIPs) were identified by a bioinformatic search for 
novel virus-encoded apoptotic regulatory molecules containing a death effector domain (DED) [39-42]. 
Following the characterization of v-FLIPs, the mammalian cellular homologue was identified and 
called c-FLIP [43]. c-FLIP, also known as Casper, iFLICE, FLAME-1, CASH, CLARP, MRIT or 
usurpin [44,45], has 13 distinct splice variants [44], three of which are expressed as proteins: the 26 kDa 
short form (c-FLIPS), the 24 kDa form of c-FLIP (c-FLIPR), and the 55 kDa c-FLIPL [24,44,45] 
(Figure 2). The structures of c-FLIPS and the v-FLIP proteins are similar, except that the two DEDs of 
c-FLIPS are followed by 20 amino acids that appear to be crucial for its ubiquitaation and targeting for 
proteasomal degradation [46]. c-FLIPR also contains two DEDs but lacks the additional carboxy 
(C)-terminal amino acids that are present in c-FLIPS. The C-terminus of c-FLIPL is longer than that of 
c-FLIPS and closely resembles the structure of caspases-8 and -10 [47,48], but this region of c-FLIPL 
does not contain a functional caspase domain. This lack of caspase activity is the result of several 
amino acids substitutions, particularly the crucial cysteine residue in the catalytic domain which is 
necessary for the catalytic activity of caspases [47]. Additionally, c-FLIPL harbors a caspase-8 
cleavage site at position Asp-376 (LEVD); c-FLIPL cleavage at this site produces the proteolytic 
fragment variant p43c-FLIP [48,49]. The C-terminal region of c-FLIPS and c-FLIPR play a crucial role 
in ubiquitnation and degradation as well as the anti-apoptotic function of these isoforms [50,51]. All 
three isoforms of c-FLIP can be recruited to the DISC through an interaction of their tandem DED 
domains with the adaptor protein FADD. Recently, Ueffing et al. [52] reported a functional single 
nucleotide polymorphism (SNP) in the human c-FLIP gene (rs10190751 A/G), located in the 3‟ splice 
consensus of intron 6, which determines c-FLIPS production. Analysis of the rs101900751 G/A 
variation in follicular lymphoma patients indicates that rs10190751 A, which directs expression of the 
c-FLIPR isoform, is associated with increased risk for this disease [52]. 
Figure 2. Structures of c-FLIP isoforms. Three c-FLIP isoforms, c-FLIPL, c-FLIPS, and 
c-FLIPR, contain two death effector domains (DEDs) at their N-termini. In addition to two 
DEDs, c-FLIPL contains a large (p20) and a small (p12) caspase-like domain without 
catalytic activity. c-FLIPS and c-FLIPR consist of two DEDs and a small C-terminus [36]. 
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3.2. Transcription and Translation of c-FLIP 
Transcriptional activation of c-FLIP can be mediated by various signal transducers, including TNF 
ligands, growth factors, interleukins, chemokines, and chemotherapeutic agents [24]. Several 
transcription factors are known to transcriptionally regulate the c-FLIP gene [24,45]. These include 
NF-κB, p53 tumor suppressor protein, p63, E2F1, c-myc, IRF5, c-Fos, nuclear factor of activated T 
cells (NFAT), heterogeneous nuclear ribonucleoprotein K (hnRNP k), the forkhead transcription factor 
FOXO3a [42], Early growth response-1(EGR1), androgen receptor (AR), E2F, AP-1, and SP1 [24,45]. 
While NF-kB, p63, NFATc2, EGR1, hnRNP K, AR and SP1 are known to induce c-FLIP expression, 
c-myc, Foxo3a, c-Fos, IRF5, and SP3 suppress c-FLIP transcription [24,45]. p53 may transcriptionally 
upregulate the c-FLIP gene and also promote the degradation of c-FLIP protein [53,54]. Intriguingly,  
c-FLIPS was highly induced upon activation of T cells, primarily via the calcineurin-NFAT pathway [55]. 
Moreover, the human T-cell leukemia virus type 1 (HTLV-1)Tax protein up-regulating c-FLIP 
expression in HTLV-1-infected cells through activation of NF-κB [56]. 
Li et al. [57] reported that c-FLIPL is transcriptionally regulated by the activator protein-1 (AP-1) family 
member protein c-Fos, and that MG-132, an inhibitor of the proteasome, sensitizes TRAIL-resistant 
prostate cancer cells by inducing c-Fos and repressing c-FLIPL. Moreover, c-Fos, which is activated by 
MG-132, negatively regulates c-FLIPL by direct binding to the putative promoter region of the c-FLIPL 
gene. In addition to activating c-Fos, MG-132 also activates c-Jun, another AP-1 family member. 
c-Fos heterodimerizes with c-Jun to form an AP-1 complex that represses transcription of c-FLIPL. 
E2F1, a transcription factor that plays a crucial role during S phase progression and apoptosis, 
triggers apoptosis in various lung adenocarcinoma cell lines by specifically downregulating of c-FLIPS 
leading to caspase-8 activation at the DISC [58]. Moreover, the SC35 splicing factor, which is a direct 
transcriptional target of E2F1, is involved in downregulation of c-FLIPS [59]. The specific 
overexpression of c-FLIPS is also seen in human lung adenocarcinomas with low levels of E2F1 [58]. 
Delineating the role of SC35 in regulating the expression of c-FLIPS will be very significant, not only 
for understanding how alternative splicing of the c-FLIP gene occurs, but also to possibly decrease the 
level of c-FLIPS by modulating SC35 expression.  
c-FLIPS is also regulated at the translational level. Panner et al. [60,61] showed that TRAIL 
resistance in glioblastoma multiforme cells (GBM) is the result of
 
c-FLIPS overexpression, and that 
activation of the Akt mammalian
 
target of rapamycin (mTOR)-p70 S6 kinase 1 (S6K1) pathway leads 
to increased translation of the c-FLIPS protein. Conversely,
 
inhibition of mTOR or its target
 
S6K1 
suppressed polyribosomal accumulation of c-FLIPS mRNA, c-FLIPS
 
protein expression, and promoted 
TRAIL resistance in GBM cells. An mTOR-independent pathway can also act through a Ral effector 
protein, RalBP1 to suppress cdc42-mediated activation of S6 kinase and the translation of the c-FLIPS 
protein [61,62]. Moreover, it has been shown that Rocaglamide (Roc) sensitizes resistant adult T-cell 
leukemia/lymphoma (ATL) cells to DR4- and DR5-mediated apoptosis by translational suppression of  
c-FLIPS [63,64] through inactivation of the translation initiation factor 4E (eIF4E) [64]. 
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3.3. c-FLIP Degradation 
c-FLIP isoforms are short lived proteins whose stability is subject to isoform-specific regulation.  
c-FLIP is predominately degraded by the ubiquitin-proteasome degradation system [24,45,50]. Both  
c-FLIP isoforms can be degraded by the proteasome, but c-FLIPS appears to be particularly sensitive to 
ubiquitination and proteasomal degradation, partly due to two crucial lysine residues in the C-terminal 
20 amino acids that are unique to c-FLIPS [50]. The sensitivity of c-FLIPS to ubiquitin-mediated 
degradation adds a novel concept to DISC regulation and its control of apoptosis [50]. 
Expression of c-FLIPL and c-FLIPS is also regulated by JNK activation via the E3 ubiquitin ligase 
Itch [24,45,65] under the control of JNK, polyubiquitinates c-FLIP to target it for degradation at the 
proteasome [65]. Phosphorylation events also play important roles in the regulation of c-FLIP protein 
levels. For instance, protein kinase C phosphorylation at the serine 193 (S193) residue of the c-FLIPS 
isoform inhibits its polyubiquitination, stabilizes c-FLIPS levels, and increases cell survival [66].  
S193 phosphorylation was markedly increased by treatment with the PKC activator  
12-O-tetradecanoylphorbol-13-acetate and decreased by inhibition of PKCα and PKCβ. 
Phosphorylation of S193 residue also decreased the ubiquitination of c-FLIPL but did not affect its 
stability, indicating that S193 phosphorylation has a different function in c-FLIPL than c-FLIPS. 
Moreover, Wang et al. [67] showed that pretreatment with the PKCδ-selective inhibitor rottlerin or 
transfection with PKCδ siRNA inhibited phorbol myristate acetate (PMA)-induced c-FLIP expression, 
which identifies a role for PKCδ in c-FLIP induction. These authors demonstrated a critical role for 
PKCδ/NF-κB in the induction of c-FLIP in human colon cancer cells. Downregulation of  
AMP-activated protein kinase also triggers ubiquitination and proteasome degradation of c-FLIP [68]. 
3.4. Upregulation of c-FLIP in Human Cancers 
Increased expression of c-FLIP has been shown in cell lines from various types of cancers including 
colorectal [69,70], pancreatic [71,72], ovarian [73,74], gastric [75], breast [76,77], prostate [78], 
melanoma [79], glioblastoma [80], and it is implicated in TRAIL resistance and chemotherapy 
resistance. Gastric cancer SNU-216 cells [12], some pancreatic cancer cell lines [71], breast cancer 
cells [76,77], and leukemia cells [7,16] express high levels of c-FLIPL and c-FLIPS. FLIPS is also a key 
suppressor of TRAIL-induced apoptosis in human glioblastoma multiforme (GBM) cell lines and 
xenografts [60]. Furthermore, elevated levels of c-FLIP in tumor tissue from patients with colorectal 
cancer [80,81], bladder urothelial cancer [82], cervical cancer [83], Burkitt‟s lymphoma [84], 
non-Hodgkin‟s lymphoma[85], and head and neck squamous cell carcinoma (HNSCC) [86], and have 
been correlated with a poor clinical outcome and could be a reliable prognostic factor in these type of 
cancer. Overexpression of c-FLIP is also seen in gastric cancer and plays an important role in lymph 
node metastasis, which ultimately contributes to the tumor progression [87]. c-FLIP is expressed in 
pancreatic intraepithelial neoplasm lesions as well as in pancreatic ductal adenocarcinomas, whereas 
normal pancreatic ducts were consistently negative for c-FLIP expression [71]. 
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3.5. c-FLIP Function 
3.5.1. c-FLIP prevents apoptosis 
Studies with animal models have revealed that c-FLIP plays an important role in T cell proliferation 
and heart development [88,89]. Moreover, abnormal c-FLIP expression has been found in various 
diseases such as cancer, multiple sclerosis, Alzheimer's disease, diabetes mellitus, and rheumatoid 
arthritis [24,44]. c-FLIP is also thought to be the main causal factor of “immune escape” [90]. c-FLIP 
is involved in TRAIL, Fas, TNF-α, and chemotherapeutic drug resistance in a wide range of human 
malignancies [24,44,72,91]. Moreover, studies using c-FLIP-deficient mice support a dual function for 
c-FLIPL by confirming a role for c-FLIP in Fas L, TNF-α-induced and apoptosis and revealing that c-
FLIP has a similar function to caspase-8 in heart development [89]. Nonetheless, a now extensive 
literature encompassing diverse types of human cancer cells indicates that the action of c-FLIP is 
generally anti-apoptotic in cancer cells. Furthermore, interference with c-FLIP expression sensitizes 
tumor cells to death ligands and chemotherapy in experimental models [24,45,91-94]. In addition to its 
function as an apoptosis modulator, c-FLIP exerts other cellular functions including increased cell 
proliferation and tumorigenesis [24,45,48,94-96] (Figure 1). 
While the precise mechanism of c-FLIP regulation of apoptosis remains elusive, the profound 
structural differences between human c-FLIP variants clearly indicate distinct regulatory roles for  
c-FLIPL and c-FLIPS in apoptosis. In fact, c-FLIPS inhibits TRAIL-induced DISC formation and 
apoptosis [24,45,48], while c-FLIPL is responsible for the above described dual functions whereby it 
inhibits Fas-induced caspase-8 activation when expressed at high levels, but enhances caspase-8 
activation when its expression level is low [24,45]. These opposing c-FLIPL functions may reflect 
observations that c-FLIPL activates caspases-8 and -10 in vitro by forming heterodimeric enzyme 
molecules with a substrate specificity and catalytic activity indistinguishable from caspase-8 
homodimers, despite the fact that c-FLIPL is protease dead [24,97,98]. Recent reports have clearly 
demonstrated that c-FLIPS also plays a central role in preventing cancer cell apoptosis. c-FLIPS has 
been shown to inhibit oxaliplatin-induced apoptosis through the sustained XIAP protein level and Akt 
activation [99]. c-FLIPS also suppresses apoptosis by inhibiting caspase-8 activation [100-102], 
although at different levels of procaspase-8 process [103,104]. c-FLIPL induces a conformation of 
procaspase-8 that triggers partial but incomplete proteolytic processing, while in contrast, c-FLIPS 
even prevents partial procaspase-8 activation at the DISC [8]. Using an in vitro induced proximity 
assay, Boatright et al. [97] provide evidence that c-FLIPL is an activator of caspase-8/-10 and 
demonstrate that the resulting heterodimer is enzymatically active with a substrate specificity identical 
to that of the caspase-8 homodimer. 
We recently discovered that c-FLIPL interacts with DR5, FADD, and caspase-8 forming an 
apoptotic inhibitory complex (AIC) in MCF-7 breast cancer cells [76]. Moreover, silencing the c-FLIP 
gene by a specific siRNA leads to death ligand-independent but DR5-, FADD-, and caspase-8- and  
-9-dependent apoptosis in these cells. Furthermore, we showed that the knockdown of c-FLIP expression 
inhibits breast cancer cell proliferation and triggers spontaneous apoptosis by activating both the death 
receptor and mitochondrial pathways [76]. Our data support the previous report by Jin et al. [105] 
demonstrating that the peptide corresponding to the DR5 binding domain of c-FLIPL induces apoptosis 
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in cancer cells. Therefore, inhibiting the interaction of DR5 and c-FLIPL by peptides or small molecule 
inhibitors should provide a mechanism by which tumor selective apoptosis can be achieved. 
Interestingly, a recent report also identified a checkpoint of the autophagy pathway where cellular and 
viral FLIPs could limit the Atg3-mediated step of LC3 ubiquitin-like protein conjugation to regulate 
autophagosome biogenesis. Furthermore, the c-FLIP-derived short peptides hold promise as new 
cancer therapeutic agents since they induced growth inhibition by binding to and effectively 
suppressing Atg3-c-FLIP interactions [106]. 
3.5.2. c-FLIP augments cytoprotective pathways 
As shown in Figure 1, c-FLIP activates several cytoprotective signaling pathways involved in 
regulating cell survival, proliferation, and carcinogenesis. Overexpression of c-FLIPL activates NF-κB 
and ERK signaling by binding to adaptor proteins in each pathway, such as TNFR-associated factors 1 
(TRAF1) and 2 (TRAF2), receptor-interacting protein 1 (RIP), and Raf-1 [48,107] (Figure 1). The 
caspase-8 processed N-terminal fragment of c-FLIPL (p43cFLIP) is more efficient than c-FLIPL at 
recruiting TRAF2 and RIP1, leading to more robust NF-κB activation [48,49,108,109]. Golks et al. [110] 
showed that in nonapoptotic cells, c-FLIP and the procaspase-8 heterodimer result in a novel  
NH2-terminal fragment
 
of c-FLIP (p22-FLIP) which is the key mediator
 
of NF-κB activation by 
binding directly to the IKK complex. These
 
results provide a new mechanism of c-FLIP-mediated NF-κB 
activation. Recently, Chang et al. [111] demonstrated that TNF-α-mediated JNK activation increases 
turnover of the NF-κB-induced c-FLIP. This is not the result of direct c-FLIP phosphorylation, but 
rather depends on JNK-mediated phosphorylation and activation of the E3 ubiquitin ligase Itch which 
specifically ubiquitinates c-FLIP and induces its proteasomal degradation. Thus, JNK antagonizes  
NF-κB during TNF-α signaling by promoting the proteasomal elimination of c-FLIPL. 
Akt is a serine-threonine kinase that plays a major role in transducing cellular survival signals and 
also regulates a number of proteins involved in the apoptotic signaling pathways. Recent results 
showed that Akt interacts with c-FLIPL protein and that c-FLIPL enhances anti-apoptotic Akt functions 
by modulating Gsk3β activity. Moreover, through its effects on Gsk3β, c-FLIPL overexpression in 
cancer cells induced resistance to TRAIL. This effect is mediated by regulation of p27(Kip1) and 
caspase-3 expression [112]. Downregulation of the DNA-PK/Akt pathway was also reported to 
correlate with high responsiveness to TRAIL-mediated growth inhibition and apoptosis [113].  
siRNA-mediated suppression of DNA-PKcs or treatment with 4,5-dimethoxy-2-nitrobenzaldehyde 
(DMNB), a specific inhibitor of DNA-PK, led to decreased phosphorylation of Akt and Bad (a target 
molecule of Akt), increased expression of DR4/DR5, and down-regulation of c-FLIP [113]. Therefore, 
inhibition of the DNA-PK/Akt pathway may have clinical usefulness in treating TRAIL-resistant 
cancer cells. [97]. 
Panner et al. [114] initially reported that a novel phosphatase and tensin homologue (PTEN)-Akt-
atrophin-interacting protein 4 (AIP4) pathway regulates c-FLIPS ubiquitination and stability in 
glioblastoma multiforme (GBM) cell lines and xenografts. However, how PTEN and Akt are linked to 
AIP4 activity was unclear. Recently, these authors described a second regulator of ubiquitin 
metabolism, the ubiquitin-specific protease 8 (USP8) which is a downstream target of Akt, and it links 
Akt to AIP4 and the regulation of c-FLIPS stability [115] (Figure 3). Overexpression of USP8 
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increased c-FLIPS ubiquitination, decreased FLIPS half-life, decreased FLIPS steady-state levels, and 
decreased TRAIL resistance (Figure 3). Therefore, PTEN appears to use control of ubiquitination to 
regulate TRAIL sensitivity in GBM cells. 
Figure 3. Schematic model of PTEN-mediated control of c-FLIPS ubiquitination and TRAIL 
sensitivity. (A). USP8 interacts with AIP4 which can ubiquitinate c-FLIPS leading to its 
degradation; (B). Increase in pAkt decreases USP8 expression, turns off the USP8/AIP4 
ubiquitin switch, resulting in c-FLIPS accumulation.  Modified from Panner et al. [114]. 
 
c-FLIPL also interacts with Daxx (a death domain-associated protein that has been implicated in 
proapoptosis and transcriptional regulation) and prevents Fas-induced JNK activation [116]. Thus, 
c-FLIPL acting on both the FADD- and Daxx-mediated signaling pathways may be involved in 
completely inhibiting Fas-induced cell death. Furthermore, Nakajima et al. [117] demonstrated that 
c-FLIPL directly interacts with a JNK activator, MAP kinase kinase 7 (MKK7), in a TNF-α-dependent 
manner and inhibits the interactions of MKK7 with MAP/ERK kinase kinase 1 (MEKK1), apoptosis-
signal-regulating kinase 1, (ASK1) and TGF-β-activated kinase 1. This interaction of c-FLIPL with 
MKK7 might selectively suppress JNK activation (Figure 1). 
Another regulator of the c-FLIP expression is the calcium/calmodulin-dependent protein kinase II 
(CaMK II) which mediates the upregulation of c-FLIP, thereby protecting cancer cells from  
TRAIL-induced apoptosis. Treating resistant cells with the CaMK II inhibitor KN-93 inhibited CaMK 
II activity, reduced c-FLIP expression, inhibited c-FLIP phosphorylation, and rescued Fas agonistic 
antibody (CH-11) sensitivity [118,119]. Targeting this pathway may provide novel therapeutic 
strategies in treating cancers with upregulated CaMK II.
 
Interestingly, phosphorylation of c-FLIP 
variants by CaMK II appears to promote c-FLIPL recruitment to the DISC and inhibit TRAIL-induced 
apoptosi [118,119], but phosphorylation of c-FLIPL by protein kinase C or the bile acid 
glycochenodeoxycholate results in decreased c-FLIPL recruitment to the DISC and increased the 
sensitivity of hepatocellular carcinoma cells to TRAIL-triggered apoptosis [120]. Thus, the particular site 
of phosphorylation on c-FLIPL appears to influence the functional outcome of this protein on apoptosis. 
Increased expression of c-FLIP can alter cell cycle progression and enhance cell proliferation and 
carcinogenesis [121,122] (Figure 1). Overexpression of c-FLIPL inhibited the ubiquitination and 
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proteasomal degradation of β-catenin, resulting in an increase in the target gene cyclin D1, colony 
formation, and invasive activity in prostate cancer cells. The c-FLIP/β-catenin/cyclin D1 signals 
contributing to colony formation and invasion were reversed by selective silencing of c-FLIP 
expression [123]. Similarly, c-FLIPL, in cooperation with FADD, enhances canonical Wnt signaling by 
inhibiting proteasomal degradation of β-catenin, thus suggesting a new mechanism involved with 
tumorigenesis [123]. Recent results also suggest a role for nuclear c-FLIPL in the modulation of Wnt 
signaling [124]. Interestingly, a deficiency in the adenomatous polyposis coli (APC) gene and 
subsequent activation of β- catenin can also lead to repression of c-FLIP expression through activation 
of c-Myc [125], c-FLIP upregulation may contribute to the carcinogenesis and aggressiveness of 
endometrial carcinomas and may serve as a useful prognostic factor for this tumor [24,126]. 
Wang et al. [127] demonstrated that c-FLIP overexpression is also significantly related to the presence 
of high-risk human papillomavirus (HR-HPV) infection during the progression of cervical squamous 
cell cancer and that c-FLIP is an early marker of cervical carcinogenesis. Moreover, HPV16 E2 protein 
interacts with and abrogates the apoptosis inhibitory function of c-FLIP and renders cervical cancer 
cell lines hypersensitive to Fas/FasL apoptosis. Overexpression of c-FLIP rescues cervical cancer cells 
from apoptosis induced by human HPV16 E2 protein expression [112]. This observation is greatly 
significant for developing therapeutic strategies to silence c-FLIP for intervention with cervical 
carcinogenesis [128]. Furthermore, overexpression of c-FLIPL also increases the hypoxia-inducible 
factor-1α (HIF1α) [129]. Overexpression of HIF1α can result in regulation of genes responsible for 
global changes in cell proliferation, metastasis, and invasion. Moreover, c-FLIP overexpression 
accelerated progression to androgen independence by inhibiting apoptosis in LNCaP prostate tumors 
implanted in nude mice [130]. 
Accumulating information clearly demonstrates that c-FLIPS plays a major role in causing 
resistance to death ligands and chemotherapeutic agents. Park et al. [131] reported that MEK1/2 
inhibitors synergistically interacted with the heat shock protein 90 (HSP90) inhibitor, geldanamycins 
[17-allylamino-17-demethoxygeldanamycin (17AAG) and 17-dimethylaminoethylamino-17-demethoxy-
geldanamycin], to kill hepatoma and pancreatic carcinoma cells. Treatment of cells with MEK1/2 
inhibitors and 17AAG reduced expression of c-FLIPS that was connected to loss of MEK1/2 and AKT 
function. Moreover, overexpression of c-FLIPS or Inhibition of caspase-8 abolished cell killing by 
MEK1/2 inhibitors and 17AAG. Interestingly, Panner et al. [132] reported that HSP90α recruits  
c-FLIPS to the death-inducing signaling complex (DISC) and contributes to TRAIL resistance. 
Furthermore, combinations of low doses of sorafenib and vorinostat increased CD95 surface levels and 
CD95 association with caspase-8 and knockdown of CD95 or FADD expression reduced 
sorafenib/vorinostat cell death [133]. Signaling by CD95 caused protein kinase R (PKR)-like 
endoplasmatic reticulum kinase (PERK) activation that was responsible for both promoting caspase-8 
association with CD95 and increased eIF2α phosphorylation. Suppression of eIF2α function abolished 
drug combination lethality. Cell killing was paralleled by PERK-and eIF2α-dependent lowering of  
c-FLIPs protein levels while overexpression of c-FLIPS maintained cell viability [133]. Similarly, 
Zhang et al. [134] showed that expression of phosphorylation-insensitive eIF2α-S51A blocked 
sorafenib- and vorinostat-induced suppression of c-FLIPS levels and overexpression of c-FLIPS 
abolished lethality. Overexpression of c-FLIPS function suppressed cell death by the multinuclear 
platinum chemotherapeutic BBR3610 [135]. 
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3.5.3. c-FLIP increases cell motility 
Another important role of c-FLIP is its involvement in increasing cancer cell motility. The role of  
c-FLIP in cell motility has been investigated using a c-FLIP-specific siRNA. Shim et al. [136] showed 
that siRNA-mediated down-regulation of c-FLIPL correlated with increased levels of reactive oxygen 
species (ROS), while over-expression of c-FLIPL triggered the opposite effect. ROS generated by 
silencing c-FLIP induced phosphorylation of Akt and impaired cell motility [136]. The role of c-FLIP 
in the motility of HeLa cells was also shown using siRNA directed against c-FLIP. Silencing c-FLIPL 
but not c-FLIPS inhibited the adhesion and motility of the cells by activating FAK and extracellular 
regulated kinase (ERK), and increasing MMP-9 expression [137]. Additional evidence demonstrating 
the role of c-FLIPL in triggering cell motility was recently provided in ovarian tumors [73]. In these 
tumors, c-FLIPL played a role in chaperoning tumor cells from immunosurveillance and increasing 
their invasive potential by augmenting cell motility [73]. 
3.5.4. c-FLIP triggers epithelial-mesenchymal transition (EMT) 
EMT is a process that induces morphological and genetic changes of cancer cells from an epithelial 
to a mesenchymal phenotype, which forms the basis for the metastatic potential of tumor cells [138]. 
Various tumor microenvironmental factors, including cytokines, growth factors, and chemotherapeutic 
agents trigger EMT [138], and this process is believed to be partly responsible for the chemotherapy-
resistant phenotype [138,139]. A cancer-associated antigen gene (CAGE) which is widely expressed in 
various cancer tissues and cancer cell lines regulates expression of EMT-related proteins through ERK, 
Akt and NF-kB [140,141]. Snail, an EMT-related protein, mediates the effect of CAGE by inducing 
matrix metalloproteinase-2 (MMP-2) and cancer cell motility. Interestingly, c-FLIP mediates the effect of 
CAGE on the induction of MMP-2 and cell motility by the induction of Snail [141].  
3.6. c-FLIP as a Therapeutic Target for Cancer Treatment 
Ectopic expression of c-FLIP variants decreased apoptosis caused by death ligands and anticancer 
agents [24], indicating that overexpression of these proteins may cause resistance to multiple 
anticancer drugs. Therapeutic modalities that lower the threshold of cancer cell apoptosis should lead 
to more effective cancer treatment. For example, strategies to inhibit the expression of c-FLIP variants 
not only trigger apoptosis in certain cancer types, but also sensitize cancer cells to chemotherapeutic 
agents, potentially allowing lower doses to be administered to patients and decreasing drug-induced 
systemic toxicities. Therefore, c-FLIP variants are critical apoptosis regulators that can serve as targets 
for small molecule inhibitors that downregulate their expression and serve as effective targeted 
therapeutics for cancer treatment. In order to support this hypothesis, our in vivo results showed that 
injecting liposomal complexes of c-FLIP-specific siRNA into MCF-7 xenografts eliminated the 
neoplastic cells without affecting the normal stromal and fibroblastic cells [142]. There does not 
appear to be a „„handle‟‟ to inhibit c-FLIP function with small molecule ligands since, as discussed 
above, c-FLIP has significant structural similarity to caspase-8. This resemblance with caspase-8 
makes c-FLIP protein a very difficult target for drugs to inhibit its function, since small molecules 
capable of blocking c-FLIP‟s recruitment to the DISC could also inhibit the recruitment of caspase-8, 
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and as a result inhibit apoptosis. Therefore, to reduce or inhibit c-FLIP expression, small molecules 
which target c-FLIP without inhibiting caspases-8 and -10 are needed. 
Small molecule therapeutics that selectively downregulate c-FLIPS or c-FLIPL and gene therapy 
strategies that knock down a specific c-FLIP variant have been used to downregulate these variants. 
Developing these innovative therapeutic strategies in conjunction with TRAIL and chemotherapeutic 
agents could potentially overcome the barrier of dose-limiting toxicity in cancer chemotherapy. TRAIL 
or chemotherapy resistance in diverse cancer cell types can be reversed by parallel treatment with 
agents known to downregulate c-FLIP variants. As discussed below and shown in Tables 1 and 2, 
c-FLIP variants can be inhibited by compounds that inhibit their transcription or translation, trigger 
their degradation, or by c-FLIP-specific small interfering RNA (siRNA) which sensitize a wide range 
of cancer cell types to TRAIL and chemotherapy-induced apoptosis. 
Table 1. Agents known to inhibit c-FLIP expression at the transcription level. 
Mechanism of action Agent References  
Generation of DNA adduct 
formation, intra- and 
interstrand crosslinks 
Cisplatin, oxaliplatin [69,70,143-
146] 
DNA intercalator Doxorubicin [147] 
Topoisomerase I inhibitor Camptothecin, 9-nitrocamptothecin (9-NC), 
irinotecan 
[69,148] 
Histone deacetylase inhibitor Vorinostat, trichostatin, droxinostat (CMH), 
valproic acid, NCH-51, MS-275, romidepsin 
(FK228/depsipeptide), and AR-42 
[149-154] 
Anti-microtubule targeting  
agent  
Lupeol (triterpene) [155-157] 
Inhibitor of IκB kinase (IKK) 
and NF-κB pathways 
Celastrol, zerumbone, withaferin A, quinacrine [158-160] 
Inhibitor of TNFα-mediated 
NF-κB activation 
Chrysin (flavonoid) [161] 
Inhibitor of mitogen-induced 
proliferative response  
S-adenosylmethionine (SAMe) 
5‟-methylthioadenosine (MTA) 
[162] 
Inhibitor of signal transducer  
and activator of transcription 
3 (STAT3) 
CDDO-imidazolide (synthetic triterpenoid) 
 
[163] 
Ras/mTOR inhibitor Salirasib [164] 
Table 2. Agents known to inhibit c-FLIP expression by post-transcriptional mechanisms. 
Mechanism of action Agent References 
Blockade of mRNA translation and 
RNaseH-mediated cleavage, with 
subsequent degradation of the 
mRNA:antisense DNA heteroduplex 
Antisense oligonucleotide  
[60] 
c-FLIP RNA interference SiRNAs 
[24,45,116, 
165,166] 
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Table 2. Cont. 
Mechanism of action Agent References 
Inhibitor of mammalian target of 
rapamycin (mTOR) 
Rapamycin 
[83] 
Inhibitor of phosphorylation of (Roc) 
translation initiation factor 4E (eIF4E) 
Disrupts the eIF4E/eIF4G association 
Rocaglamide 
[87] 
Antimicrotubule agent Taxol (paclitaxel) [7] 
Protein synthesis inhibitors 
Cyclohexamide and 
anisomycin 
[167] 
RNA synthesis inhibitor Actinomycin D [168,169] 
Thymidylate synthase (TS) inhibitor 5-fluorouracil (5-FU) [8,122] 
PPARγ modulation 
CDDO, 15-deoxy-δ (12,14)-
prostaglandin J2 (15d-PGJ2),  
Rosiglitazone, Troglitazone 
[170-174] 
Proteasome inhibitors PS-34 (bortezomib), MG-132  [80,175-186] 
Bcr-Abl kinase inhibitor Imatinib mesylate [187,188] 
Blocks the activation of NF-κB and 
TGF-β1/Smad signaling pathways 
Silibinin (flavonoid) 
[189] 
Induces cyclin D1 phosphorylation, 
Increases ubiquitination of c-FLIP 
SHetA2 
[190] 
Akt and NF-κB downregulation Genistin (isoflavone) [191] 
Multikinase inhibitor Sorafenib [192] 
Inhibitor of AKT phosphorylation Eupatolide [193] 
Elevation of c-Jun N-terminal kinase 
(JNK) and its substrate c-Jun  
α-TEA  
[194,195] 
Inhibitor of transglutaminase 2 (TG2) Cystamine [196] 
Proteasome-mediated degradation of c-
FLIPS 
Paxilline 
[197] 
Inhibitor of phosphorylation of AKT 
(pAKT) and cellular FLICE-like 
inhibitory protein (c-FLIP)  
Tamoxifen 
[198] 
Increases reactive oxygen species 
(ROS) and induces proteasome-
dependent degradation of c-FLIP 
Isoquinoline alkaloid, 
Berberine (BBR) 
 
[199] 
Activator of signal transduction 
cascades 
INF-γ 
[200] 
Induce ROS, activator of both death 
receptor- and mitochondrial-mediated  
apoptotic pathways 
β-elemene piperazine 
derivatives 
[201] 
EGFR tyrosine kinase inhibitor  AG1478 [202] 
Down-regulates STAT3 
Kahweol, a coffee-specific 
diterpene 
[203] 
Phosphodiesterase inhibitor Pentoxifylline (PTX) [204] 
Phosphatidylinositol 3'-kinase inhibitor LY294002 [205] 
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3.6.1. c-FLIP transcriptional regulators for cancer therapy 
As shown in Table 1, DNA damaging agents are promising drugs with regard to downregulating 
levels c-FLIP variants. Pretreatment with chemotherapeutic drugs including cisplatin, doxorubicin, or 
topoisomerase I inhibitors (camptothecin, 9-NC, irinotecan) downregulated c-FLIP variants expression 
in various tumor cells by inhibiting its transcription and rendering cells sensitive to death receptor-
triggered apoptosis (Table 1) [69,143-148]. Successful inhibition of malignant cell growth and 
apoptosis induction using histone deacetylase inhibitor (HDACi) compounds has highlighted the 
potential use of these compounds as anticancer agents. Several HDACi have been shown to 
downregulate c-FLIP expression in various cancer cells at the transcriptional and translational 
levels [149-152]. Among these, suberoylanilide hydroxamic acid (SAHA, vorinostat) is the most 
promising HDACi that causes robust inhibition of c-FLIP variants [149]. Recent results demonstrated 
that TRAIL-triggered apoptosis in breast cancer cells is blocked at the level of apical activation of 
caspase-8, and that SAHA enhances the TRAIL-induced processing and activation of procaspase-8. 
Interestingly, degradation of c-FLIPL and c-FLIPS by an ubiquitin/proteasome-dependent Itch/AIP4-
independent mechanism is observed upon exposure to SAHA [149]. We recently showed that a new 
HDACi 4-(4-Chloro-2-methylphenoxy)-N-hydroxybutanamide (CMH) or droxinostat [151,152], 
identified using a highthroughput chemical library screen [153,154], triggered apoptosis in the breast 
cancer cell line MCF-7 through c-FLIPL and c-FLIPS mRNA as well as protein downregulation [151]. 
Interestingly, this agent induced more robust apoptosis in a doxorubicin-resistant variant of MCF-7 
cells [151]. As shown in Table 1, a number of agents with modulating effects on Akt, PI3K, NF-κB, 
and Ras pathways, as well as an inhibitor of STAT3 have also been shown to transcriptionally silence 
c-FLIP expression. 
3.6.2. Oligonucleotide and RNAi-targeting of c-FLIP for cancer therapy 
We have shown that CCRF-HSB-2 human lymphoblastic leukemia cells transfected with an 
antisense c-FLIP plasmid abrogated c-FLIPS and c-FLIPL expression and triggered a significant 
increase in Taxol-induced apoptosis [7]. Logan et al. [143] investigated whether using an antisense 
oligonucleotide to target c-FLIP was a clinically feasible approach (Table 2). These authors developed 
a novel c-FLIP-targeted antisense phosphorothioate oligonucleotide (AS PTO) and recently used it in 
vitro in transient transfection experiments and in vivo using xenograft models in Balb/c nude mice [143]. 
The AS PTO downregulated c-FLIP and resulted in caspase-8 activation and apoptosis induction in 
non-small cell lung cancer (NSCLC) cells, but not in normal lung cells. Similar results were observed 
in colorectal and prostate cancer cells. The AS PTO also sensitized cancer cells but not normal lung 
cells to apoptosis induced by TRAIL and increased chemotherapy-triggered apoptosis in NSCLC cells. 
Importantly, compared to a control non-targeted PTO, intraperitoneal delivery of c-FLIP AS PTO 
inhibited the growth of NSCLC xenografts and enhanced the in vivo antitumor effects of cisplatin. 
Therefore, this c-FLIP-targeted AS PTO may have potential for further pre-clinical development.  
The development of RNA interference (RNAi)-based therapeutics to target the c-FLIP gene in vivo 
may change the way cancers are treated by inducing apoptosis [79] or by sensitizing cancers to 
chemotherapeutic agents. However, difficulties in siRNA design, delivery, and stability must be solved 
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before RNAi-based therapeutics will be feasible for clinical use. We have used lipocomplexes of 
c-FLIP siRNA to successfully knock down the c-FLIP gene and induce spontaneous apoptosis in 
MCF-7 breast cancer cells in vitro [142] (Table 2), and in vivo by directly injecting the c-FLIP siRNA 
lipocomplexes into MCF-7 mouse xenografts [142]. Lipocomplexes of c-FLIP siRNA have also been 
used to successfully silence the c-FLIP gene and trigger spontaneous apoptosis in A549 lung cancer 
cells [165], HCT116 colorectal cancer cells [166], and LNCaP and PC3 prostate cancer cells [13]. 
Furthermore, c-FLIP siRNA lipocomplexes injected into HCT116 colorectal tumor xenografts 
decreased tumor growth [166]. These studies show that c-FLIP siRNA lipocomplex formulations can 
be used to successfully knock down the c-FLIP gene in various cancer cell types [76,95]. 
3.6.3. c-FLIP degradation as a target for cancer therapy 
As discussed above, c-FLIP is predominately degraded by the ubiquitin-proteasome system. 
Downregulation of c-FLIPL and c-FLIPS due to degradation is observed in cells treated with various 
apoptosis-inducing agents (Table 2). Cycloheximide [167] and anisomycin [153], two protein synthesis 
inhibitors, as well as the RNA synthesis inhibitor actinomycin D [168] have been shown to 
downregulate c-FLIPL and c-FLIPS. Treating cancer cells with fluorouracil (5-FU) was also 
demonstrated to downregulate both isoforms in colon cancer cell lines [106,169] (Table 2). 
Peroxisome proliferator-activated receptor γ (PPARγ) agonists sensitize cancer cells to TRAIL by 
ubiquitination and proteasome-dependent c-FLIP degradation [170-174]. Tiwary et al. [77] recently 
reported that α-tocopherol ether-linked acetic acid analogue (α-TEA) downregulation of c-FLIP is 
mediated by ER stress-dependent JNK/CHOP/DR5 signaling via JNK activation of Itch E3 ligase 
ubiquitination and involved in activation of the ER-stress-dependent events via reducing the inhibitory 
effect of c-FLIP on caspase-8. 
Proteasome inhibitors are a new class of drugs that decrease proliferation and induce apoptosis in a 
variety of hematologic and solid malignancies [175-186]. Interestingly, several proteasome inhibitors 
lead to the downregulation of c-FLIPL and c-FLIPS [24,45,172]. The induction of apoptosis by the 
proteasome inhibitors MG-132 and PS-341 (bortezomib, Velcade
®
) in primary chronic lymphocytic 
leukemia (CLL) cells and the Burkitt lymphoma cell line BJAB was associated with upregulation of 
TRAIL and its death receptors, DR4 and DR5, and decreased c-FLIP protein expression [179]. 
Similarly, bortezomib decreased c-FLIP expression in multiple myeloma and human esophageal 
squamous cell carcinoma cell lines [180,181]. However, the effect of PS-341 on the regulation of 
c-FLIP expression may be cancer cell-type specific. In contrast to what was observed human esophagil 
cancer cell lines, Liu et al. reported that PS-341 upregulates DR5 as well as c-FLIP and survivin in 
human non-small cell lung carcinomas (NSCLC) cells [183]. As discussed earlier, c-FLIP is degraded 
via a ubiquitin-proteosome system. Therefore, PS-341 should increase c-FLIP and prevent apoptosis. 
Interestingly, Zhao et al. have shown that PS-341 decreases c-FLIP at the gene level [184]. 
The Bcr-Abl kinase inhibitor imatinib mesylate (formerly known as CGP 57148B, STI571, or 
Gleevec) is currently the standard therapy for chronic myeloid leukemia (CML). Hamaı et al. [187] 
reported that Imatinib mesylate increases human melanoma cell sensitivity to TRAIL-induced cell 
death by directly downregulating protein levels of c-FLIP variants. Interestingly, Park et al. [188] 
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showed that silencing the Bcr-Abl in K562 leukemia cells led to the downregulation of c-FLIPL and 
subsequent increase to TRAIL sensitivity. 
As shown in Table 2, a number of agents known to affect various targets and signaling pathways in 
cancer cells also cause degradation of c-FLIP variants (189-205).  Moreover, several compounds have 
been shown to inhibit expression of c-FLIP variants, but whether these agents cause degradation of 
these proteins or silence their transcription remain to be found. Nutlin-3, a small molecule antagonist 
of MDM2 which inhibit the p53-MDM2 interaction and activates p53 signaling was recently shown to 
decrease expression of c-FLIPS and c-FLIPL and was synergistic with TRAIL in triggering cell death 
[206]. Moreover, Ozarelix, a gonadotropin-releasing hormone antagonist [207], celecoxib, a 
cyclooxygenase-2 inhibitor [208], the chemopreventive agent, all-trans-retinyl acetate (RAc) [125], 
smac mimetic compounds (SMC) [180], and sunitinib, an orally administered tyrosine kinase inhibitor 
(TKI) [210] decreased expression of c-FLIP. Furthermore, downregulation of c-FLIP by a specific 
microRNAs (i.e., miR-512-3p) increased taxol-induced apoptosis [211], supporting our previous report 
that silencing c-FLIP variants increases Taxol-triggered apoptosis [7]. Gemcitabine was also recently 
shown to inhibit expression of c-FLIP variant in pancreatic cancer cells [71], but whether it inhibits the 
transcription, enhances degradation, or prevents translation of c-FLIP remains to be found. 
Figure 4. ATM kinase activity downregulates c-FLIPL and c-FLIPS at the protein level and 
connects DNA damage signaling to TRAIL-induced apoptosis signaling pathway. DNA 
damaging agents induce ATM activation, which promotes c-FLIPL protein degradation and 
c-FLIPS downregulation through an unknown mechanism (Stagni et al. [122]).  
 
Recent data [122,212,213] clearly demonstrate that ataxia telangiectasia mutated (ATM) kinase 
activity modulates c-FLIPL and c-FLIPS protein levels in response to DNA damage (Figure 4). 
Moreover, the radiomimetic drug Neocarzinostatin (NCS) may trigger the down-regulation of c-FLIP 
isoforms by inducing the activation of the ATM kinase in response to DNA damage [122]. ATM 
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kinase activity negatively modulates the stability of c-FLIPL and c-FLIPS at the protein level, thereby 
promoting the sensitivity to apoptosis induction by Fas (CD95/APO-1), a TRAIL-R1/R2-related death 
receptor [213]. NCS-triggered decrease in c-FLIP resulted in increased sensitivity to TRAIL which 
was inhibited by ATM kinase activity inhibition [122]. Upon NCS treatment, ATM promotes c-FLIPL 
protein degradation through the ubiquitin-proteasome system but the mechanism of degradation of 
c-FLIPS that ATM is linked to remains to be determined [122]. 
4. Conclusions 
It is now evident that c-FLIP variants induce resistance to death receptor ligands and 
chemotherapeutic agents in various cancer cells and that c-FLIP may be a relevant clinical target for 
counteracting therapy resistant human malignancies. The current state of the art reviewed in this article 
suggests that targeting c-FLIP in combination with TRAIL or standard chemotherapies has therapeutic 
potential for treating human cancers. As discussed, various classes of agents can downregulate c-FLIP 
expression. However, c-FLIP has significant structural similarity to caspase-8; this makes c-FLIP a 
very difficult target for developing drugs that inhibit this protein directly, since small molecules 
capable of blocking c-FLIP‟s recruitment to the DISC could simultaneously inhibit the recruitment of 
caspase-8 and thereby inhibit apoptosis. Therefore, to reduce or inhibit c-FLIP expression, small 
molecules which target c-FLIP without inhibiting caspases-8 and -10 are needed. Compounds that 
inhibit or downregulate c-FLIP mRNA expression will particularly be of interest. As discussed above, 
employing a high-throughput chemical screening strategy, a small molecule inhibitor of c-FLIP, 
4-(4-Chloro-2-methylphenoxy)-N-hydroxybutanamide (CMH) or droxinostat has been identified that 
downregulates c-FLIPL and c-FLIPS mRNA and protein levels, reduces cell survival, and induces 
apoptosis. The foregoing discussion justifies optimism that future cancer therapy will be improved by 
innovations that combine chemotherapy with drug resistance-reversing multi-targeted therapy, 
e.g., combination regimens of chemotherapy and small molecule drugs that downregulate c-FLIP. 
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